Ajay Subramanian, BS

Stanford University
Stanford, California, United States

Disclosure information not submitted.

Presentation(s):

• Paper 81 - PEMBROLIZUMAB, RADIOTHERAPY, & SURGERY VS RADIOTHERAPY & SURGERY FOR STAGE III SOFT TISSUE SARCOMA OF THE EXTREMITY: OUTCOMES & SARCOMA IMMUNE CLASS ANALYSIS IN SU2C-SARC032 RANDOMIZED CLINICAL TRIAL

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 83 - PHASE 1 STUDY OF INTRATUMORAL BO-112 AND NIVOLUMAB IN RESECTABLE SOFT TISSUE SARCOMA UNDERGOING HYPOFRACTIONATED PREOPERATIVE RADIOTHERAPY

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 87 - CELLSARCTX: A SINGLE-CELL TRANSCRIPTOMICS ATLAS OF ADOPTIVE CELLULAR THERAPY TARGETS IN SOFT TISSUE SARCOMAS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 96 - PERSONALIZED CTDNA ANALYSIS IS ASSOCIATED WITH OUTCOMES AFTER PREOPERATIVE RADIOTHERAPY WITH OR WITHOUT PEMBROLIZUMAB FOR STAGE 3 SOFT TISSUE SARCOMAS ON SU2C-SARC032

  Saturday, November 16, 2024
  2:00 PM – 3:00 PM PST

• Paper 97 - CELL-FREE TUMOR DNA FROM SURGICAL WASHINGS AS A BIOMARKER OF LOCAL RECURRENCE AFTER RESECTION

  Saturday, November 16, 2024
  2:00 PM – 3:00 PM PST